Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Sleep Disruption on Drug Response
Sponsor: Johns Hopkins University
Summary
The central scientific premise of the proposed study is that sleep disruption (SD) will influence individuals' subjective response to blinded medication administration. The investigators further believe these responses will vary among patients who have chronic low back pain (CLBP) vs. healthy controls, and that sex will moderate effects. The proposed study evaluates whether CLBP patients' subjective responses to study medication administration are altered by SD. The investigators focus on two outcome domains: abuse liability (i.e., drug liking and valuation) and response to pain testing. The investigators propose a mixed between-within randomized crossover human-laboratory experiment that investigates placebo-controlled effects of study medication on 1) abuse liability metrics (Drug Liking and Monetary Valuation) and 2) response to laboratory-evoked standardized pain measures, after one night of uninterrupted sleep (US) and again after one night of SD. The investigators will recruit both CLBP patients(\*) and healthy controls (N = 60). (\*) We originally aimed to accrue 60 subjects with CLBP. However, we have been granted approval by the National Institute on Drug Abuse (NIDA) to reduce expectations for the target N for the CLBP cohort. We are no longer expected to recruit N=60 CLBP participants; this is a COVID-19 modification, and we are not required to re-do a power analysis.
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
109
Start Date
2019-10-07
Completion Date
2025-04-29
Last Updated
2026-10-21
Healthy Volunteers
Yes
Conditions
Interventions
Within-Subject test of blinded study medication
On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. Participants receive up to four injections, starting with placebo (saline). This is followed by ascending doses of Hydromorphone (0.14, 0.28, and 0.56mg/70kg). This study uses a within-subject design, such that participants serve as participants' own control.
Locations (1)
Johns Hopkins School of Medicine
Baltimore, Maryland, United States